检测还是不检测?为患者提供胚胎植入前非整倍体遗传学检测(PGT-A)咨询的框架
这项回顾性队列研究纳入2014年12月至2016年9月的600例患者,比较首次IVF周期开始时意向选择PGT-A者与匹配对照的单次取卵累积活产率。结果显示,<38岁患者PGT-A组单次取卵累积活产率显著低于对照(49.4% vs 69.1%,P<0.001),而≥38岁患者两组单次取卵累积活产率相似,但每移植活产率翻倍(62.1% vs 31.7%,P<0.001)。
要点
- <38岁首次IVF周期意向PGT-A者单次取卵累积活产率显著低于对照。
- ≥38岁PGT-A组单次取卵累积活产率与对照相似,每移植活产率翻倍。
- PGT-A组与对照分别有25.3%和2.3%未获得移植。
核心结论
- 首次IVF周期开始时选择PGT-A会降低<38岁患者单次取卵的累积活产率,但≥38岁患者每移植活产率显著获益。
- 作者认为PGT-A可能对<38岁首次IVF周期患者不利,在≥38岁人群获得移植时临床影响最大。
- 该研究评估患者周期开始时选择PGT-A后的典型治疗路径,可作为按年龄和周期数咨询患者的参考。
研究设计与样本
- 回顾性队列研究,时间范围为2014年12月至2016年9月,共纳入600例患者,其中首次IVF周期意向PGT-A者300例及匹配对照。
- 研究在一家大型学术附属不孕症诊所进行,约80%患者拥有生育治疗保险覆盖。
- 患者按年龄、取卵时间和获卵数匹配至同等数量的对照。
- 事后效能计算(α=0.05,效能0.80)表明研究有足够效能显示单次取卵累积活产率和每移植活产率的显著差异。
主要发现
- 首次周期<38岁患者中,意向PGT-A组单次取卵累积活产率显著低于对照(49.4% vs 69.1%,P<0.001)。
- ≥38岁患者中,PGT-A组单次取卵累积活产率与对照相似,每移植活产率是对照的两倍(62.1% vs 31.7%,P<0.001)。
- 首次周期PGT-A组和对照组分别有25.3%和2.3%未能获得移植。
临床怎么用
- 作者认为PGT-A可能对<38岁首次IVF周期患者不利。
- 作者认为PGT-A在≥38岁人群获得移植时临床影响最大。
- 该研究可作为按年龄和周期数咨询患者的参考。
局限性
- 由于回顾性性质,本研究并非真正的意向性治疗研究。
- PGT-A组有两次或以上既往流产史的患者数显著多于对照,但亚组分析显示这未影响结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the treatment path and cumulative live birth (CLB) rate from a single oocyte retrieval of patients who intend to pursue PGT-A at the start of an IVF cycle compared to matched controls? SUMMARY ANSWER: The choice of PGT-A at the start of the first IVF cycle decreases the CLB per oocyte retrieval for patients <38 years of age, however patients ≥38 years of age benefit significantly per embryo transfer (ET) when live birth (LB) is evaluated. WHAT IS KNOWN ALREADY: PGT-A has been shown to reduce the practice of transferring multiple embryos and to confer a higher live birth rate per transfer. STUDY DESIGN, SIZE, DURATION: This is a retrospective cohort study from December 2014 to September 2016, involving 600 patients: those intending PGT-A for their first IVF cycle (N = 300) and their matched controls. Post-hoc power calculations (alpha of 0.05, power of 0.80) indicated that our study was powered adequately to demonstrate significant differences in CLB per retrieval and LB per transfer. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study was performed at a large academically affiliated infertility practice where approximately 80% of patients have insurance coverage for fertility care. Patients were identified through electronic medical records, and those who intended to pursue PGT-A at the start of stimulation were assessed. Patients were matched by age, time of oocyte retrieval and oocyte yield to the same number of controls. CLB outcomes per single retrieval, including the fresh and frozen transfers arising from the initial stimulation cycle, were calculated. MAIN RESULTS AND THE ROLE OF CHANCE: PGT-A was not beneficial when CLB rate was assessed per retrieval, however its benefits were significant when LB rate was assessed per transfer. First cycle, <38 year-old patients who intended to have PGT-A had a significantly (P < 0.001) lower CLB rate per oocyte retrieval compared to controls (49.4% vs. 69.1%). Conversely, patients ≥ 38 years in the PGT-A group had similar CLB rates compared to controls per oocyte retrieval, while LB rates per transfer were doubled compared to controls (62.1% vs. 31.7%; P < 0.001). Of the first-cycle PGT-A and control patients, 25.3% and 2.3% failed to achieve a transfer, respectively. LIMITATIONS, REASONS FOR CAUTION: This is not a true intention-to-treat study, due to its retrospective nature. Additionally, the number of patients with two or more previous miscarriages was significantly greater in the PGT-A group as compared to controls, however a sub-analysis showed that this failed to impact outcomes. WIDER IMPLICATIONS OF THE FINDINGS: The findings indicate that PGT-A may be detrimental for those <38 years old undergoing their first IVF cycle. PGT-A has the greatest clinical impact when a transfer is achieved in the ≥38 years old population. This study evaluates the typical treatment path following a patient's choice to pursue PGT-A at the cycle start, and can be used as a guide for counselling patients in relation to age and cycle number. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.
引用
- Murphy LA, Seidler EA, Vaughan DA, et al. To test or not to test? A framework for counselling patients on preimplantation genetic testing for aneuploidy (PGT-A). Hum Reprod. 2019. PMID: 30500907. doi:10.1093/humrep/dey346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。